FDA De Novo vs 510(k): Key Differences, Costs & Best Pathway Guide
Choosing between FDA De Novo vs 510(k) is one of the most critical strategic decisions a medical device manufacturer will make when entering the United States market. Misjudging your regulatory classification can trigger costly FDA Refuse-to-Accept (RTA) decisions, unwanted clinical trial demands, and multi-million-dollar commercial delays.
As medtech innovation accelerates—particularly across Software as a Medical Device (SaMD), artificial intelligence (AI/ML), and novel diagnostic tools—determining whether your product requires demonstrating substantial equivalence or establishing a new risk classification is essential.
This guide provides an end-to-end comparison of the FDA De Novo vs 510(k) pathways, evaluating predicate rules, submission costs, review timelines, and strategic selection frameworks.
Get Expert Compliance Guidance
What is an FDA 510(k) Premarket Notification?
The FDA 510(k) pathway is the most common regulatory route for medical device market clearance in the U.S., governed under 21 CFR Part 807.
A 510(k) submission requires a manufacturer to demonstrate that their device is substantially equivalent (SE) to a legally marketed “predicate device” in the United States.
When to Choose the 510(k) Pathway:
A valid, legally marketed U.S. predicate device exists.
Your device shares the same intended use as the predicate.
The device utilizes similar technological characteristics—or technological differences do not introduce new questions of safety and effectiveness.
Advantages of FDA 510(k):
Shorter Review Timeline: Standard FDA review time is 90 calendar days (excluding user fee review holds).
Lower Financial Burden: Reduced FDA user fees and lower pre-market clinical testing requirements compared to PMA or De Novo routes.
Predictable Approval Route: Clear historical guidance and technical benchmarks established by existing predicate submissions.
Manufacturers preparing for Premarket Notification can leverage structured FDA 510(k) submission support to streamline bench testing, labeling, and technical gap analyses.
What is the FDA De Novo Classification Pathway?
The FDA De Novo pathway (under Section 513(f)(2) of the FD&C Act) provides a regulatory mechanism to classify novel medical devices that are low-to-moderate risk (Class I or Class II) but lack an existing, legally marketed predicate device.
Without the De Novo process, any novel device lacking a predicate would automatically default to Class III (high risk), requiring an extensive and costly Premarket Approval (PMA).
When to Choose the De Novo Pathway:
Comprehensive search confirms no legally marketed predicate device exists in the FDA database.
The device presents low-to-moderate risk (qualifying for Class I or Class II classification).
Safety and effectiveness can be assured through General Controls or by establishing product-specific Special Controls (e.g., performance standards, guidance documents, or post-market monitoring).
Strategic Advantage of FDA De Novo:
Upon successful De Novo authorization, the FDA creates a brand-new product code and regulation number. Your device becomes the first-in-class predicate for all future 510(k) submissions, creating a formidable competitive barrier for late entrants.
FDA De Novo vs 510(k): Direct Comparison
| Feature / Criteria | FDA 510(k) Premarket Notification | FDA De Novo Classification |
| Predicate Device | Mandatory (Must identify legally marketed SE device) | None (Novel device with no predicate) |
| Device Risk Classification | Typically Class II (some Class I/III) | Class I or Class II (Low-to-moderate risk) |
| Regulatory Outcome | FDA 510(k) Clearance | De Novo Grant (Creates a new device classification) |
| Standard FDA Review Timeline | ~90 Calendar Days | ~150 Calendar Days |
| Standard FDA User Fee (FY 2026) | Lower Fee Tier | Higher Fee Tier (Approx. 5x-6x of 510(k)) |
| Data Requirements | Bench testing, software, biocompatibility, rare clinical data | Robust benefit-risk analysis, non-clinical & clinical performance data |
| Market Positioning | Fast market entry for me-too / modified devices | First-mover advantage; establishes future industry predicate |
Cost & Timeline Breakdown: FDA De Novo vs 510(k)
Understanding the total financial investment for FDA De Novo vs 510(k) involves factoring in statutory user fees, testing costs, and regulatory consulting fees:
1. FDA Statutory User Fees (MDUFA)
FDA MDUFA fees are updated annually. De Novo submissions command significantly higher user fees due to the extensive scientific review required to establish new special controls:
Standard 510(k) User Fee: ~$21,800+ (Small businesses receive up to 75% fee reductions).
Standard De Novo User Fee: ~$145,000+ (Small business fee discounts apply with certified SBD status).
2. Testing and Clinical Evidence Costs
510(k) Testing Investment: Focuses on comparative bench testing, electrical safety (IEC 60601-1), software validation, and biocompatibility (ISO 10993).
De Novo Testing Investment: Requires demonstrating primary safety and clinical performance profiles. If your device incorporates combination features, aligning with CE marking for drug-device combinations or international standards helps optimize cross-market clinical testing budgets.
Similarly, if expanding internationally alongside U.S. filings, review our guide to European regulatory pathways under CE Marking for EU MDR.
Speak with a Regulatory Expert Today
💡 Need guidance on identifying predicate devices or choosing between 510(k) and De Novo?
How to Determine Your Ideal FDA Pathway
Follow this decision matrix during early device development:
Perform a Rigorous Predicate Search: Search the FDA 510(k), De Novo, and PMA databases using Product Codes, 510(k) summaries, and Regulation Numbers.
Submit an FDA Q-Submission (Pre-Sub): When predicate equivalence or testing scope is uncertain, submit a formal Pre-Submission to request written feedback and a meeting with the FDA review team.
Establish Design Controls & QMS: Regardless of whether you pursue 510(k) or De Novo, implementing a compliant ISO 13485 QMS and FDA QMSR (21 CFR Part 820) framework is legally required prior to commercial distribution.
If your product involves complex integrated systems, ensure your quality baseline accounts for a unified QMS perspective for drug-device combinations.
How Operon Strategist Can Help
Operon Strategist provides end-to-end regulatory strategy, quality management, and medical device clearance consulting for global markets:
Regulatory Pathway Assessment: Conducting comprehensive predicate database searches, gap analyses, and classification strategies to determine 510(k), De Novo, or PMA eligibility.
FDA Pre-Submission (Q-Sub) Management: Authoring Pre-Sub packages and leading official meeting discussions with the FDA to validate testing plans before filing.
Dossier Authoring & Submission: Complete preparation of 510(k) Premarket Notifications and De Novo Classification requests, including eSTAR formatting.
FDA QMSR & ISO 13485 Setup: Establishing compliant Quality Management Systems covering Design Controls (21 CFR 820.30), Risk Management (ISO 14971), and Supplier Management via ISO 13485 QMS implementation.
Global Regulatory Expansion: Connecting U.S. FDA clearances with international approvals, including CDSCO India regulatory registration, EU MDR compliance, and turnkey medical device facility setup.
🚀 Unsure which FDA pathway fits your medical device technology?
Schedule Your Strategy Call With Operon Strategist
FAQ's
What is the primary difference between FDA De Novo vs 510(k)?
A 510(k) requires demonstrating substantial equivalence to an existing predicate device, whereas De Novo is used for novel, low-to-moderate risk devices without a predicate.
Can a De Novo authorized device be used as a predicate for future 510(k)s?
Yes. Once granted, a De Novo device establishes a new classification and product code, serving as a predicate for future 510(k) submissions.
How long does FDA clearance take for 510(k) vs De Novo?
FDA review time for a 510(k) is typically ~90 calendar days, while a De Novo submission takes approximately ~150 calendar days.
Is the FDA De Novo pathway more expensive than 510(k)?
Yes. FDA statutory user fees for De Novo are significantly higher than 510(k) fees, and clinical or bench testing requirements are typically more extensive.
What happens if the FDA rejects a 510(k) due to lack of a predicate?
If the FDA determines a device is Not Substantially Equivalent (NSE) due to lack of a predicate, the manufacturer can submit a De Novo classification request.